Gregory M. Videtic MD, CM, FRCPC, FACR, FASTRO Section Head for Thoracic Malignancies and Residency Program Director in the Department of Radiation Oncology from the Cleveland Clinic explains the ASTRO 2020 Abstract 2192 Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early Stage Lung Cancer.Link to the Poster -https://astro.multilearning.com/astro/2020/annualmeeting/299139?evname=u42P5_6f3xRUr5o4erxthw&evsign=qHSlYUSOTWdeKOP7_nrA0o8Ly2HKhzA2gN9W3g-RXrkBody Purpose / Goal(s):To study single-institution outcomes for medically inoperable peripheral early-stage lung cancer after ten years of single-fraction lung SBRT (SF-SBRT), prompted by the recent publication of randomized phase II trials in which this fractionation was evaluated.Methods/Materials:In 12/2009, our first SF-SBRT pt was treated (on RPCI124407). Therefore, for the 12/2009-12/2019…
Author: Editor
Kunal Sindhu, MD from the Icahn School of Medicine at Mount Sinai speaks about the ASTRO 2020 Abstract 3009 Identifying Existing Knowledge Gaps in Palliative Radiation Oncology.Link to Poster -https://astro.multilearning.com/astro/2020/annualmeeting/299954?evname=u42P5_6f3xRUr5o4erxthw&evsign=xxA2-A3l2isLpbxsuiedLFC6WvM7vwTnWMLbgy_jeDcBodyPurpose / Objective(s): In patients with cancer, palliative radiation therapy can greatly improve symptoms and function. Previous research, however, has reported major differences with respect to palliative care in radiation oncology residency curricula. The Mednet, an online group of doctors whose aim is to “improve the exchange of information between doctors so that patients receive high-quality treatment wherever they are treated,” has become an increasingly used resource for radiation oncologists with…
Philadelphia, PA (October 28, 2020) – Oncoceutics, Inc. announced today that the first patient has been treated in a first-in-human clinical trial of the company’s next-generation imipridone ONC206 at the National Institutes of Health (“NIHâ€). The Phase I trial, for adults with recurrent primary central nervous system (CNS) neoplasms, is led by Mark Gilbert, MD, Chief of the Neuro-Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), and Brett Theeler, MD, Clinical Collaborator at the Neuro-Oncology Branch, CCR, NCI (NCT04541082).ONC206 is the second agent in the Oncoceutics pipeline to enter clinical trials.  ONC206 is part of the family…
Rahul Tendulkar, MD from the Cleveland Clinic explains the ASTRO 2020 abstract Impact of Post-Mastectomy Radiation Therapy (PMRT) in Women with T1-2N1M0 Breast Cancer: A Multi-Institutional Analysis.Link to Poster -https://astro.multilearning.com/astro/2020/annualmeeting/299020?evname=u42P5_6f3xRUr5o4erxthw&evsign=BB6is3P9G4uw30MZ7jlyksrkAKFeZEeBxQIXbHeHTQYBodyPurpose/Objective(s): To explore the impact of PMRT on women in the modern age with pT1-2N1M0 breast cancer.Materials / Methods: In order to include women who underwent mastectomy without neoadjuvant therapy with pT1-2N1M0 disease from 1995-2015, data from 5 North American institutions were pooled. Patients were divided into cohorts for discovery and confirmation. Using several imputations with chain equations, missing covariate values were imputed and combined using Rubin’s law. Regression of competing…
Samuel Chao, MD from the Cleveland Clinic, Case Comprehensive Cancer Center speaks about the ASTRO 2020 abstract 18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis.Link to Poster -https://astro.multilearning.com/astro/2020/annualmeeting/300531?evname=u42P5_6f3xRUr5o4erxthw&evsign=kydhbsVx1w4S1oU-pZ2_Z9SOEjvJQvyZiwIujHnE0tUBodyPurpose / Objective(s): To determine whether 18F Fluciclovine PET CT, a widely available FDA approved amino acid radiotracer for a suspected recurrence of prostate cancer, is useful in separating radiation necrosis (RN) from tumor progression (TP) from stereotactic radiosurgery (SRS)-treated brain metastases. Descriptive updates of an ongoing pilot clinical trial are being published.Materials / Methods: The primary objective is to estimate the precision of 18F Fluciclovine PET CT in the separation between…
Visit https://BeaconMedIC.com for more media and information.Subscribe to audio podcast at http://BTJBeacon.libsyn.com/rss/audioDrs. Charu Aggarwal and Jack West host Dr. Mark Lewis of Intermountain Healthcare to explore different styles of how physicians use social media for education, connection in building community, and determining boundaries in what to share with #MedTwitter.
Andrew Lachlan Schmidt, M.B., B.S. of Dana-Farber Cancer Institute speaks about Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer.Abstract  Renal cell carcinoma (RCC) therapies currently approved include tyrosine kinase inhibitors, immune checkpoint inhibitors, and mTOR signaling inhibitors. Increased understanding of clear cell and non-clear cell RCC biology has led to the development of agents targeting hypoxia-inducible factor 2 and MET, while ongoing exploration of targeting immune pathways other than the programmed death-ligand 1 or protein 4 control points associated with cytotoxic T-lymphocyte-associated protein 4. The development of drugs in RCC is moving towards the study of…
Prof. Byoung Chul Cho, MD, Ph.D. Yonsei Cancer Center, Yonsei University College of Medicine discusses the ESMO 2020 Abstract – Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC.Abstract 1258OContextThe combination of amivantamab (EGFR-MET bispecific antibody) with lazertinib indicates synergistic inhibition of tumor growth in preclinical studies. In phase 1 CHRYSALIS research (NCT02609776), we present the safety and early efficacy findings of patients receiving amivantamab in combination with lazertinib.MethodologyPatients with non-small cell lung cancer ( NSCLC) with EGFR Exon 19 deletion or L858R mutation were enrolled in this 2-part…
Saad Usmani, M.D., MBA, FACP, Department of Hematologic Oncology and Blood Disorders of Atrium Health Levine Cancer Institute discusses Daratumumabâ€lenalidomideâ€dexamethasone vs standardâ€ofâ€care regimens: Efficacy in transplantâ€ineligible untreated myeloma. AbstractDaratumumab has recently obtained FDA clearance for the treatment of transplant-negligible patients with newly diagnosed multiple myeloma (NDMM) in conjunction with lenalidomide-dexamethasone (D-Rd). The current PEGASUS study compared progression-free survival (PFS) in patients treated with D-Rd in the MAIA study and patients treated with common standard-of-care regimens from the de-identified database derived from the Flatiron Health electronic health record, which has data from patients treated predominantly in U.S. community-based oncology practices. In…
Petros Grivas, MD, Ph.D. of the University of Washington; Fred Hutchinson Cancer Research Center speaks about the ESMO 2020 abstract Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers.Abstract 699OContextAvelumab (anti-PD-L1 IgG1 antibody) 1L maintenance + BSC substantially extended overall survival ( OS) in the phase 3 JAVELIN Bladder 100 (NCT02603432) study vs BSC alone in patients (pts) with advanced disease-free UC progression with 1L induction chemotherapy in both randomized pts and pts with PD-L1 + tumors. We publish studies of exploratory biomarkers.MethodologyPrior to randomization,…
Ramaprasad Srinivasan, M.D., Ph.D. of the NIH National Cancer Institute speaks about the ESMO 2020 abstract Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease.Abstract LBA26ContextVHL autosomal dominant genetic disorder is characterized by germline inactivating VHL gene mutations and constitutive activation of the transcription factor HIF-2 alpha that stimulates tumor development. In this open-label phase II study (NCT03401788), MK-6482, a potent, selective, small-molecule HIF-2 alpha inhibitor, was evaluated for efficacy for the treatment of VHL-associated tumors.MethodologyQualified patients (pts) were ⇠18 years of…
Marcia S. Brose, MD, Ph.D. of the Pearlman School of Medicine at The University of Pennsylvania speaks on the ESMO 2020 abstract Larotrectinib treatment of advanced TRK fusion thyroid cancer.Abstract 1916PContextLarotrectinib is an EMA and FDA approved first-in-class, central nervous system active, highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of adult and pediatric TRK fusion cancer patients (pts). In pts with TRK fusion cancer across different tumor types (Hong et al. Lancet Oncol. 2020), Larotrectinib provided an objective response rate (ORR) of 79 percent and a median period of response (DoR) of 35.2 months. We report the…
Marcia S. Brose, MD, Ph.D. of the Pearlman School of Medicine at The University of Pennsylvania discusses the ESMO 2020 abstract Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).Abstract 1918PBackgroundIn patients with RAI-R DTC, MKIs effectively extend progression-free survival but are associated with notable toxicity. There is currently no consensus about when systemic therapy should be initiated by patients with asymptomatic RAI-R DTC.MethodologyA global non-interventional research, enrolling patients with asymptomatic RAI-R DTC, RIFTOS MKI is designed to assess…
Ian Chau, MD from Royal Marsden Hospital speaks about the ESMO 2020 abstract Initial safety and efficacy findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.1446P Abstract BackgroundIn patients with advanced gastric and gastroesophageal junction (GEJ) cancer, bavituximab, an investigational, chimeric monoclonal antibody engineered to inhibit the immunosuppressive effects of phosphatidylserine, is being tested in combination with pembrolizumab. Post-hoc findings from the phase III Sunrise second-line lung cancer trial found that overall survival was substantially improved in patients who advanced on bavituximab plus docetaxel study treatment and proceeded with a checkpoint inhibitor as the next line of…
Ian Chau, MD from Royal Marsden Hospital discusses the ASCO abstract Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.Context:In patients with advanced gastric and gastroesophageal junction (GEJ) cancer, bavituximab, an investigational, chimeric monoclonal antibody engineered to inhibit the immunosuppressive effects of phosphatidylserine (PS), is being tested in combination with pembrolizumab. To reverse immunological non-responsiveness and stimulate multiple immune cell receptors, bavituximab binds to β2-glycoprotein and PS in a high-affinity complex. Post-hoc results from the Phase III Sunrise second-line lung cancer trial showed that overall survival was substantially improved in patients who advanced…
Matthew Tucker, Clinical Fellow at Vanderbilt University Medical Center discusses Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.Quick SummaryImmunotherapy-based treatment methods for metastatic renal cell carcinoma have become the standard of care. The tumors in several patients will gradually progress, despite considerable improvement in overall survival with these therapies. This analysis highlights ongoing attempts to establish biomarkers to assist in determining which patients are most likely to benefit from immunotherapy care.AbstractThe treatment environment for metastatic renal cell carcinoma (RCC) has been altered by immunotherapy-based combinations powered by PD-1, PD-L1, and CTLA-4 inhibitors. Many patients do not achieve deep or…
Edward S. Kim, MD, FACP of the Levine Cancer Institute/Carolinas HealthCare System speaks about IASLC NACLC 2020: Boehringer Ingelheim presents new data for Gilotrif® in metastatic, squamous cell carcinoma of the lung, and in EGFR mutation-positive NSCLC.Ridgefield, Conn., October 13, 2020-Boehringer Ingelheim today announced new Gilotrif ® (afatinib) results, further confirming its activity in lung squamous cell carcinoma and non-small cell lung cancer ( NSCLC) epidermal growth factor receptor mutation-positive (EGFR M+) in a separate review. At the IASLC 2020 North America Conference on Lung Cancer organized by the International Association for the Study of Lung Cancer (NACLC 2020), the…
Arun Azad, Ph.D., MBBS, FRACP from Peter MacCallum Cancer Centre, discusses mHSPC Management, ESMO, Ongoing and Upcoming Clinical Trials in patients with metastatic hormone-sensitive prostate cancer.
Amrita Krishnan, MD, FACP of City of Hope S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)Summary Brief:Patients are registered before or after ASCT for screening (Reg Step 1), but before Reg Step 2. Patients are monitored before they begin maintenance and are then registered (first randomization) for Reg Step 2. Between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20, patients are randomized. MRD is measured after 2 years of maintenance to guide further therapy. The assigned care will be continued by MRD-positive patients. In order to either proceed or discontinue the care assigned,…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Sandip Patel joins GRACE to discuss current updates in non small cell lung cancer.In this video, Dr. Patel discusses updated information on emerging molecular targets in nsclc – EGFR Exon 20.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Patel joins GRACE to discuss current updates in non small cell lung cancer.In this video, Dr. Patel discusses updated information on emerging molecular targets in nsclc – KRAS.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates in non small cell lung cancer.In this video, Dr. Bauml discusses updated information on emerging molecular targets in nsclc – MET.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates in treatments for non small cell lung cancer.In this video, Dr. Bauml discusses updated information on emerging molecular targets in nsclc – RET fusions. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Ben Levy joins GRACE to discuss current updates in treatments for non small cell lung cancer. In this video, Dr. Levy discusses updated information on immunotherapy in patients with driver mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Ben Levy joins GRACE to discuss current updates in treatments for non small cell lung cancer. In this video, Dr. Levy discusses updated information on immunotherapy combinations for advanced nsclc. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
We are excited to bring you more new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD.For this video, Dr. Ramy Sedhom speaks with with Dr. Petros Grivas from the University of Washington and Fred Hutchinson Cancer Center. In this video, Drs Sedhom and Grivas discuss Muscle Invasive Bladder Cancer.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Kessler, from the University of Colorado Cancer Center. In the second part of this two part conversation, Drs. Sedhom and Kessler continue the discussion on muscle invasive bladder cancer in the elderly. For more, please visit http://cancerGRACE.org/. If you have questions or comments, please feel free to join the conversation at https://cancergrace.org/forums/bladder-cancer.
We are excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD.For this video, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Kessler, from the University of Coloradeo Cancer Center. In part one of this two part conversation, Drs. Sedhom and Kessler discuss muscle invasive bladder cancer in the elderly. For more, please visit http://cancerGRACE.org/.If you have questions or comments, please feel free to join the conversation at https://cancergrace.org/forums/bladder-cancer.
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la información más reciente sobre el cuidado del cáncer de pulmón.En este video, el Dr. Raez analiza la inmunoterapia en pacientes con mutaciones conductoras.Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Luis E. Raez provides us with the…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la información más reciente sobre el cuidado del cáncer de pulmón.En este video, el Dr. Raez analiza las principales opciones de tratamiento para pacientes con tumor negativo PD-L1 en 2020.Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Luis…
Nos complace ofrecer más adiciones a nuestra Biblioteca de videos sobre cáncer de pulmón para nuestra comunidad de habla hispana.Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la información más reciente sobre el cuidado del cáncer de pulmón.En este video, el Dr. Raez analiza la utilidad de las biopsias lÃquidas en 2020.Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.*****We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Translating Molecular Oncology Results into Targeted Therapy TreatmentFor the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Luis E. Raez provides us with the latest information in lung cancer care. In this video, Dr. Raez discusses translating molecular oncology results into targeted therapy treatments in precision medicine. *****Avances en Biologia Molecular Convirtiendose en Sucessos de Terapia Blanco Medicina de PrecisPara conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la información más reciente sobre el cuidado del cáncer de pulmón. En este video, el Dr. Raez analiza las opciones de tratamiento actuales para el SCLC recidivante en 2020.Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library, produced in Spanish for…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, la Dra. Estelamari RodrÃguez nos brinda la información más reciente sobre el cuidado del cáncer de pulmón. En este video, el Dr. RodrÃguez nos actualiza sobre objetivos moleculares emergentes en NSCLC: fusiones RET, MET, KRAS, inserciones del exón 20 de EFGR.Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library,…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las adiciones más recientes a nuestra Videoteca sobre el cáncer de pulmón, producidas en español para nuestra comunidad latina, la Dra. Estelamari RodrÃguez nos brinda la información más reciente en el cuidado del cáncer de pulmón. En este video, el Dr. RodrÃguez nos actualiza sobre la terapia de protones para el NSCLC localmente avanzado.Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr.…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las adiciones más recientes a nuestra Videoteca sobre el cáncer de pulmón, producidas en español para nuestra comunidad latina, la Dra. Estelamari RodrÃguez nos brinda la información más reciente en el cuidado del cáncer de pulmón. En este video, el Dr. RodrÃguez nos actualiza sobre las combinaciones de inmunoterapia para el NSCLC avanzado en 2020.Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community,…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las adiciones más recientes a nuestra Videoteca sobre el cáncer de pulmón, producidas en español para nuestra comunidad latina, la Dra. Estelamari RodrÃguez nos brinda la información más reciente en el cuidado del cáncer de pulmón. En este video, el Dr. RodrÃguez analiza la inmunoterapia para el cáncer de pulmón de células pequeñas.Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Estelamari…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las nuevas incorporaciones a nuestra videoteca de cáncer de pulmón, producida en español para nuestra comunidad latina, la Dra. Estelamari RodrÃguez nos brinda la información más reciente sobre la atención del cáncer de pulmón. En este video, el Dr. RodrÃguez analiza el estado actual de la carga mutacional tumoral en 2020 como un factor de respuesta predictivo.Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.*****For the newest additions to our Lung Cancer Video Library, produced in Spanish for our…
In part three of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19. GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19, and the challenges and future outlook for in-person patient care. Part 1 – How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care Part 2 – Update on the Use of Telemedicine in Patient Care During the Pandemic Part 3 – Challenges and the Future Outlook for…
In part two of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss an update on the use of telemedicine in patient care during the pandemic.Part 1 – How Has the Coronavirus Pandemic Changed Cancer Management in Patient CarePart 2 – Update on the Use of Telemedicine…
In part one of this three part video series update, presented in July of 2020, GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss changes to management in patient care, the use of telemedicine and future challenges, as well as other issues relating to a cancer diagnosis in the middle of a pandemic. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Zhu discusses whether preoperative immunotherapy could improve outcomes in early stage non small cell lung cancer. ***** Zhu Mojun Zhuåšå£«åŠ å…¥GRACE任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ï¼Œä»¥å‘我们的普通è¯è‚ºç™Œè§†é¢‘库æ供信æ¯ã€‚ 在æ¤è§†é¢‘ä¸ï¼Œæœ±åšå£«è®¨è®ºäº†æœ¯å‰å…疫疗法是å¦å¯ä»¥æ”¹å–„早期éžå°ç»†èƒžè‚ºç™Œçš„预åŽã€‚ For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. 有关更多信æ¯ï¼Œè¯·è®¿é—®http://cancerGRACE.org/。è¦åŠ 入对è¯ï¼Œè¯·è®¿é—®https://cancergrace.org/forum。
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Zhu discusses if immunotherapy can help patients with small cell lung cancer. ***** Zhu Mojun Zhuåšå£«åŠ å…¥GRACE任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ï¼Œä»¥å‘我们的普通è¯è‚ºç™Œè§†é¢‘库æ供信æ¯ã€‚ 在æ¤è§†é¢‘ä¸ï¼Œæœ±åšå£«è®¨è®ºäº†å…疫疗法是å¦å¯ä»¥å¸®åŠ©å°ç»†èƒžè‚ºç™Œæ‚£è€…。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. 有关更多信æ¯ï¼Œè¯·è®¿é—®http://cancerGRACE.org/。è¦åŠ 入对è¯ï¼Œè¯·è®¿é—®https://cancergrace.org/forum。
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Zhu discusses if immunotherapy can help frail patients with advanced NSCLC. ***** Zhu Mojun Zhuåšå£«åŠ å…¥GRACE任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ï¼Œä»¥å‘我们的普通è¯è‚ºç™Œè§†é¢‘库æ供信æ¯ã€‚ 朱医生在这段视频ä¸è®¨è®ºäº†å…疫疗法是å¦å¯ä»¥å¸®åŠ©å¼±åŠ¿çš„晚期éžå°ç»†èƒžè‚ºç™Œæ‚£è€…。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. 有关更多信æ¯ï¼Œè¯·è®¿é—®http://cancerGRACE.org/。è¦åŠ 入对è¯ï¼Œè¯·è®¿é—®https://cancergrace.org/forum。
æŽä»å¦®åšå£«åŠ å…¥GRACE，担任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ç»™æˆ‘们的普通è¯è‚ºç™Œè§†é¢‘库。 在æ¤è§†é¢‘ä¸ï¼ŒæŽåŒ»ç”Ÿè®¨è®ºäº†å“ªäº›æ™šæœŸNSCLC患者今天仅是一线å…疫治疗的好人选。 ***** Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li discusses which patients with advanced NSCLC are good candidates for first line immunotherapy alone today. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. è¦åŠ 入对è¯ï¼Œè¯·è®¿é—®https://cancergrace.org/forum。
æŽä»å¦®åšå£«åŠ å…¥GRACE，担任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ç»™æˆ‘们的普通è¯è‚ºç™Œè§†é¢‘库。 在æ¤è§†é¢‘ä¸ï¼ŒæŽåŒ»ç”Ÿè®¨è®ºäº†å½“今低PD-L1肿瘤表达低或阴性和晚期鳞状NSCLC患者的主è¦æ²»ç–—选择。 有关更多信æ¯ï¼Œè¯·è®¿é—®http://cancerGRACE.org/。è¦åŠ 入对è¯ï¼Œè¯·è®¿é—®https://cancergrace.org/forum。 ******* Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li discusses the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC today. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this addition to the GRACE Lung Cancer Video Library, Dr. Millie Das, Professor of Medicine, Division of Hematology and Oncology at UCSF in San Francisco joins us to discuss the current leading treatment options for patients with low or negative tumor PDL1 expression and advanced non-squamous non small cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this addition to the GRACE Lung Cancer Video Library, Dr. Millie Das, Professor of Medicine, Division of Hematology and Oncology at UCSF in San Francisco joins us to give updated information on the current role of immunotherapy for unresectable stage 3 non small cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced non-squamous NSCLC today. æŽä»å¦®åšå£«åŠ å…¥GRACE，担任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ç»™æˆ‘们的普通è¯è‚ºç™Œè§†é¢‘库。 在æ¤è§†é¢‘ä¸ï¼ŒæŽåšå£«åˆ†äº«äº†æœ‰å…³ä½ŽPD-L1肿瘤表达或低水平NSCLC晚期患者的主è¦æ²»ç–—选择的信æ¯ã€‚ For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
æŽä»å¦®åšå£«åŠ å…¥GRACE，担任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ç»™æˆ‘们的普通è¯è‚ºç™Œè§†é¢‘库。 在æ¤è§†é¢‘ä¸ï¼ŒæŽåŒ»ç”Ÿåˆ†äº«äº†æ™šæœŸNSCLC和高肿瘤PD-L1表达患者的主è¦æ²»ç–—选择的信æ¯ã€‚ Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on the leading treatment options for patients with advanced NSCLC and high tumor PD-L1 expression. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.